Search

everythinglearnresearchcommunity

for

Search:↓

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

The user has been using finasteride for 18 years to manage hair loss and is considering starting minoxidil and possibly a hair transplant. Despite some regrowth, they are exploring additional treatments like dutasteride and oral minoxidil due to continued hair thinning.

A 20-year-old started taking 1mg oral finasteride and 3mg oral minoxidil every other day for hair loss. They plan to focus on their hair and health over the summer and will update in November.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

The conversation discusses the best ethanol and propylene glycol ratio for homemade topical finasteride, with a focus on absorption and drying issues. The user shares their experience using a 50% propylene glycol, 30% ethanol, and 20% water solution, and considers adjusting the ethanol content for better results.

A 23-year-old is considering using a topical solution of Finjuve (finasteride and minoxidil) at a reduced dosage of 0.2/0.4mg to treat crown thinning while minimizing side effects. Applying 0.1-0.2 mL is suggested to lower systemic absorption and effectively reduce DHT on the scalp.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A 20-year-old is using dutasteride, minoxidil, finasteride with stemoxydine, alfatradiol, ketoconazole shampoo, and dermapen for hair loss and is considering mixing these treatments to save time. They are also contemplating a hair transplant that requires 3500 grafts.

A 19-year-old has seen hair regrowth after 10 months using finasteride and recently added minoxidil and tretinoin. They experienced no side effects from the treatments and are optimistic about further improvement.

The user has scheduled a hair transplant after stabilizing hair loss with finasteride and minoxidil, considering additional dermarolling. They are advised to use 2500-3000 grafts conservatively for temple filling without lowering the hairline too much.

A 20-year-old used 1 mg finasteride and liquid minoxidil, initially twice daily then once at night, to thicken hair, though temple regrowth was minimal. The user experienced no side effects and continued both treatments for hair improvement.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

A 20-year-old is dealing with male pattern baldness and considering finasteride despite concerns about side effects. Users recommend treatments like minoxidil, dutasteride, and lifestyle changes, stressing early intervention.

Verteporfin treatment shows promise for hair regeneration and reducing scar tissue in hair transplants. Some users plan to try verteporfin with hair transplants, and it may also be combined with PRP in future experiments.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

A user has been using finasteride since 2018, switched to dutasteride, and added minoxidil, microneedling, and a tretinoin/spiro compound. They are pleased with the results and hopeful for more improvement.

The post discusses diluting 100ml of 0.1% topical finasteride with 90ml of stemoxydine to create a 0.05% solution, aiming for a longer-lasting and potentially less side-effect-prone treatment. The user seeks feedback on this idea.

The conversation discusses the difficulty of applying tretinoin 0.025% cream on the scalp and considers switching to a gel for easier application. It also mentions that a liquid solution, ideally combined with minoxidil, may be more effective for hair treatment.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A 20-year-old is experiencing hair loss and has tried oral and topical minoxidil, finasteride, and is considering dutasteride and a hair transplant. They feel frustrated and hopeless due to the lack of results and its effect on their mental health.

The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.